

Prescribing Clinical Network

Policy Statement	Opicapone for adjunctive therapy in adult patients with Parkinson's Disease
Policy No:	PCN 320-2018
Date of Issue	January 2018
Review Date:	January 2021 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
Recommendations:	
<p>The Prescribing Clinical Network recommends Opicapone as a treatment option as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's Disease and end-of-dose motor fluctuations who cannot be stabilised on these combinations.</p> <p>Opicapone is recommended as a 2nd line treatment option (after entacapone) for the symptoms of Parkinson's Disease and a BLUE (no information sheet) traffic light status is recommended.</p> <p>Clinical responsibility for prescribing should remain with the specialist team for at least 2 months and transfer of care can be requested once the doses of Opicapone and levodopa are stabilised and the response to treatment has been reviewed.</p>	
Key Consideration:	
<ul style="list-style-type: none"> • Evidence available from 2 PHASE III trials BIPARK I & BIPARK II. Reduced off time and an increase in on time without troublesome dyskinesia. • Once daily preparation which may help to reduce pill burden in some patients. • Low incidence of adverse effects 	
Date taken to Prescribing Clinical Network	10 th January 2018
Agreed by PCN members	22 nd January 2018